About Baxalta (NYSE:BXLT)
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity14.28%
Return on Assets4.62%
Baxalta (NYSE:BXLT) Frequently Asked Questions
What is Baxalta's stock symbol?
Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."
How were Baxalta's earnings last quarter?
Baxalta Inc (NYSE:BXLT) released its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.46 by $0.01. The biotechnology company earned $1.50 billion during the quarter, compared to the consensus estimate of $1.47 billion. Baxalta had a net margin of 9.37% and a return on equity of 14.28%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 EPS. View Baxalta's Earnings History.
Has Baxalta been receiving favorable news coverage?
Media headlines about BXLT stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxalta earned a news impact score of 0.19 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Baxalta?
Shares of BXLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxalta's stock price today?
One share of BXLT stock can currently be purchased for approximately $46.02.
How can I contact Baxalta?
Baxalta's mailing address is 1200 Lakeside Dr, BANNOCKBURN, IL 60015-1243, United States. The biotechnology company can be reached via phone at +1-224-9402000.
MarketBeat Community Rating for Baxalta (BXLT)MarketBeat's community ratings are surveys of what our community members think about Baxalta and other stocks. Vote "Outperform" if you believe BXLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BXLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Baxalta (NYSE:BXLT) Dividend Information
Baxalta pays an annual dividend of $0.28 per share, with a dividend yield of 0.61%. BXLT's most recent quarterly dividend payment was Friday, July 1.
|Most Recent Dividend:||7/1/2016|
|Dividend Growth:||0.00% (3 Year Average)|
|Track Record:||2 Years of Consecutive Dividend Growth|
Baxalta (NYSE:BXLT) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Baxalta (NYSE:BXLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...